Praxis Precision Medicines (PRAX) Competitors

Praxis Precision Medicines (NASDAQ:PRAX) and Galecto (NASDAQ:GLTO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment, community ranking and analyst recommendations.

Which has higher valuation and earnings, PRAX or GLTO?

Galecto is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	N/A	N/A	-$214.03 million	-$3.86	-0.23
Galecto	N/A	N/A	-$61.62 million	-$2.27	-0.94

Does the MarketBeat Community believe in PRAX or GLTO?

Galecto received 14 more outperform votes than Praxis Precision Medicines when rated by MarketBeat users. Likewise, 62.79% of users gave Galecto an outperform vote while only 52.00% of users gave Praxis Precision Medicines an outperform vote.

Company	Underperform	Outperform
Praxis Precision Medicines	Outperform Votes 13 52.00%	Underperform Votes 12 48.00%
Galecto	Outperform Votes 27 62.79%	Underperform Votes 16 37.21%

Do insiders & institutionals have more ownership in PRAX or GLTO?

89.3% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 35.8% of Galecto shares are held by institutional investors. 10.5% of Praxis Precision Medicines shares are held by insiders. Comparatively, 9.2% of Galecto shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Do analysts recommend PRAX or GLTO?

Praxis Precision Medicines currently has a consensus price target of $10.25, indicating a potential upside of 1,068.62%. Galecto has a consensus price target of $11.67, indicating a potential upside of 445.17%. Given Praxis Precision Medicines' higher probable upside, research analysts plainly believe Praxis Precision Medicines is more favorable than Galecto.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40
Galecto	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more volatility & risk, PRAX or GLTO?

Praxis Precision Medicines has a beta of 3.01, indicating that its stock price is 201% more volatile than the S&P 500. Comparatively, Galecto has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500.

Does the media refer more to PRAX or GLTO?

In the previous week, Galecto had 2 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 2 mentions for Galecto and 0 mentions for Praxis Precision Medicines. Galecto's average media sentiment score of 0.75 beat Praxis Precision Medicines' score of 0.00 indicating that Galecto is being referred to more favorably in the news media.

Company	Overall Sentiment
Praxis Precision Medicines	Neutral
Galecto	Positive

Is PRAX or GLTO more profitable?

Galecto's return on equity of -85.49% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-190.08%	-137.72%
Galecto	N/A	-85.49%	-73.78%

Summary

Galecto beats Praxis Precision Medicines on 10 of the 15 factors compared between the two stocks.